Magnetar Financial LLC Increases Stock Position in Gilead Sciences, Inc. $GILD

Magnetar Financial LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 201.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,087 shares of the biopharmaceutical company’s stock after purchasing an additional 46,800 shares during the period. Magnetar Financial LLC’s holdings in Gilead Sciences were worth $7,780,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Capital International Inc. CA increased its position in shares of Gilead Sciences by 29.4% during the third quarter. Capital International Inc. CA now owns 357,879 shares of the biopharmaceutical company’s stock worth $39,725,000 after acquiring an additional 81,363 shares during the last quarter. Legal & General Group Plc boosted its holdings in Gilead Sciences by 4.2% in the third quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock valued at $1,133,376,000 after purchasing an additional 414,454 shares during the last quarter. Fieldview Capital Management LLC acquired a new stake in Gilead Sciences during the 3rd quarter valued at approximately $1,908,000. WINTON GROUP Ltd increased its holdings in Gilead Sciences by 47.3% during the 3rd quarter. WINTON GROUP Ltd now owns 66,742 shares of the biopharmaceutical company’s stock worth $7,408,000 after purchasing an additional 21,427 shares during the last quarter. Finally, Inceptionr LLC purchased a new stake in Gilead Sciences during the 3rd quarter worth approximately $402,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $148.56 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $184.43 billion, a price-to-earnings ratio of 21.94, a price-to-earnings-growth ratio of 1.92 and a beta of 0.37. The business has a 50 day simple moving average of $139.23 and a 200-day simple moving average of $126.30.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same period last year, the business posted $1.90 earnings per share. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio is currently 46.68%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Jefferies initiated coverage on Gilead with a Buy and $180 price target (≈21% upside vs. recent levels), which can attract fresh demand and lift sentiment among institutional investors. Jefferies coverage
• Positive Sentiment: Short interest fell ~15.7% in February to ~18.45M shares (1.5% of float), lowering potential short-squeeze dynamics and reducing downward pressure from bearish positioning; days-to-cover sits near 2.7 days based on average volume. (Data reported 3/10/2026)
• Positive Sentiment: Gilead agreed to acquire Arcellx (ACLX) for up to $7.8B — a deal meant to broaden Gilead’s cancer/ cell therapy pipeline; the acquisition signals management’s push into higher-growth oncology assets and helps explain investor buying. Gilead to acquire Arcellx
• Positive Sentiment: Market research (DelveInsight) forecasts strong expansion in the CD19 inhibitors market (oncology & autoimmune indications), supporting a favorable long-term backdrop for companies building CAR-T/ cell‑therapy franchises like Gilead. CD19 market outlook
• Neutral Sentiment: Gilead presented at the Leerink Global Healthcare Conference — the transcript may offer management color on pipeline timing, margins and M&A rationale but typically affects stock movement only after materially new guidance or data. Leerink presentation transcript
• Neutral Sentiment: Market write-ups (Yahoo/Zacks/247WallSt) noted Gilead’s outperformance and recent analyst coverage changes; these summaries reflect current momentum but are second‑order drivers unless paired with new data or ratings revisions. Market coverage

Wall Street Analyst Weigh In

Several equities analysts have recently commented on GILD shares. Needham & Company LLC reiterated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Cantor Fitzgerald upped their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Citigroup reissued a “buy” rating on shares of Gilead Sciences in a report on Friday. Finally, Rothschild & Co Redburn boosted their target price on shares of Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $157.62.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the sale, the chief financial officer owned 167,779 shares in the company, valued at $25,910,110.97. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at $1,101,620. This represents a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 309,280 shares of company stock valued at $43,935,470. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.